Your browser doesn't support javascript.
loading
Immune response elicited in the tumor microenvironment upon rMV-SLAMblind cancer virotherapy.
Moritoh, Kanako; Shoji, Koichiro; Amagai, Yosuke; Fujiyuki, Tomoko; Sato, Hiroki; Yoneda, Misako; Kai, Chieko.
Afiliación
  • Moritoh K; Laboratory Animal Research Center, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
  • Shoji K; Laboratory Animal Research Center, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
  • Amagai Y; Laboratory Animal Research Center, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
  • Fujiyuki T; Laboratory Animal Research Center, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
  • Sato H; Laboratory Animal Research Center, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
  • Yoneda M; Laboratory Animal Research Center, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
  • Kai C; Laboratory Animal Research Center, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
Cancer Sci ; 114(5): 2158-2168, 2023 May.
Article en En | MEDLINE | ID: mdl-36715555
Oncolytic virotherapy is a promising therapy for cancer. We previously established a recombinant measles virus (rMV-SLAMblind) that targets NECTIN4-expressing cancer cells and demonstrated its antitumor effects using a xenograft model in an immunodeficient mouse. In the current study, to investigate the immune response after rMV-SLAMblind therapy, we developed an immunocompetent cancer mouse model by introducing the NECTIN4 gene into mouse cancer cell lines. NECTIN4-expressing mouse cancer cells were successfully killed by rMV-SLAMblind in vitro. After transplantation of the NECTIN4-expressing tumor cells, rMV-SLAMblind significantly suppressed tumor growth in immunocompetent mice. Thus, this immunocompetent mouse cancer model could be a powerful tool in which to study the effect of rMV-SLAMblind therapy on the immune response. Using this model we found that rMV-SLAMblind elicited significant activation of natural killer cells, type 1 helper T cells and the tumor-specific CD8+ T-cell response in the tumor microenvironment. Immune cell depletion study revealed that CD8+ cells particularly played significant roles in the therapeutic efficacy of rMV-SLAMblind. Thus, rMV-SLAMblind exerts a therapeutic effect, not only directly by tumor cell killing, but also indirectly by efficient induction of antitumor immunity.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Virus Oncolíticos / Viroterapia Oncolítica / Neoplasias Límite: Animals / Humans Idioma: En Revista: Cancer Sci Año: 2023 Tipo del documento: Article País de afiliación: Japón Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Virus Oncolíticos / Viroterapia Oncolítica / Neoplasias Límite: Animals / Humans Idioma: En Revista: Cancer Sci Año: 2023 Tipo del documento: Article País de afiliación: Japón Pais de publicación: Reino Unido